FDC or isomers: C0 > 5 % of Cmax [Regulatives / Guidelines]

posted by Achievwin – US, 2024-08-05 21:08 (290 d 17:42 ago) – Posting: # 24134
Views: 2,589

❝ The ICH’s M13A will soon supersed the FDA’s guidance. However, a similar procedure is stated in its Section 2.2.3.3 Carry over.


❝ The idea of assessing the predose concentrations in higher period(s) is to check whether the washout was sufficiently long. The treatment comparison in the presence of equal/unequal carryover would – unavoidably – be biased and there is no statistical method to adjust for it.


Oh my equal/unequal carryover – never ending story

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,679 registered users;
42 visitors (0 registered, 42 guests [including 26 identified bots]).
Forum time: 14:50 CEST (Europe/Vienna)

Pharmacokinetics may be simply defined as
what the body does to the drug,
as opposed to pharmacodynamics, which may be defined as
what the drug does to the body.    Leslie Z. Benet

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5